<?xml version="1.0" encoding="utf-8"?>
<oembed>
  <version>1</version>
  <type>rich</type>
  <provider_name>Libsyn</provider_name>
  <provider_url>https://www.libsyn.com</provider_url>
  <height>90</height>
  <width>600</width>
  <title>Choosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis?</title>
  <description>This is the fifth episode of our new &amp;quot;Program on JAK Inhibitors for Atopic Dermatitis&amp;quot; series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, &amp;quot;Choosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis?&amp;quot;, featuring expert dermatologist Dr. Naiem Issa, MD, PhD, discusses the following topics:   Mechanistic differences between JAKi and biologics for treatment of AD   Clinical data supporting the safety of JAKi in head-to-head trials compared to biologics   Pearls for prescribing JAKi to AD patients   Strategies for choosing JAKi vs biologics based on safety and patient factors   </description>
  <author_name>DermDocs</author_name>
  <author_url>http://dermdocs.libsyn.com/website</author_url>
  <html>&lt;iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/32811917/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen&gt;&lt;/iframe&gt;</html>
  <thumbnail_url>https://assets.libsyn.com/secure/content/177119067</thumbnail_url>
</oembed>
